Comparative effects of raw and processed cistanche glycosides on the HPT axis and gut microbiota in a rat model of kidney-yang deficiency

作者：Xiao‐Qing Shen, Jing Lian, Chao Zhang, Yixiang Miu, Yuan Zhang, Ji Shi, Nan Xu, Tianzhu Jia · 发表于：Frontiers in Pharmacology · 年份：2025 · DOI：10.3389/fphar.2025.1597564 · 被引用次数：7 · 研究领域：Gut microbiota and health、Metabolomics and Mass Spectrometry Studies、Traditional Chinese Medicine Analysis

Introduction Kidney Yang Deficiency (KYD) is a metabolic disorder associated with kidney damage. Its slow progression means that causative factors and effective therapeutic agents remain unclear. Extensive evidence links KYD to gut microbiome metabolic diseases and the Hypothalamic-Pituitary-Thyroid (HPT) axis. Cistanche deserticola (CD) is a commonly used traditional Chinese medicine for treating KYD. However, the precise interactions between gut microbiota and KYD, as well as the mechanisms of raw and processed CD total glycosides (CDG) in modulating KYD, require further investigation. This study aims to evaluate the effects and mechanisms of CDG in a KYD rat model using 16S rRNA gene sequencing and fecal metabolomics. Methods CDG was extracted from both raw and processed CD and analyzed via HPLC. Propylthiouracil-induced KYD rats were used to assess pharmacological effects, including serum levels of T 3 , T 4 , TSH, TRH, FFA, LPL, and NO; organ indices of the spleen, kidney, and thymus; blood cAMP/cGMP levels; and liver levels of glycogen, SDH, Ca 2+ -ATPase, and Na + -K + -ATPase. Immunohistochemistry was also performed. Results Fecal non-targeted metabolomics identified 98 metabolites associated with KYD, while 16S rRNA sequencing revealed 13 key intestinal microbiotas linked to KYD. CDG therapy effectively alleviated KYD symptoms by modulating the gut microbiota, improving metabolic and microbial imbalances in KYD. RG/WG significantly improves KYD rats mainly through th...